Development of meloxicam potassium-containing co-spray-dried inhalation powder with sodium stearate
Pulmonary drug delivery (PDD) has potential for both local and systemic therapy. Our research group is focus- ing on the development of dry powder inhalation (DPI) systems for PDD due to their beneficial properties. Although there is not yet a marketed inhalation product for non-steroidal anti-infla...
Elmentve itt :
| Szerzők: | |
|---|---|
| Dokumentumtípus: | Cikk |
| Megjelent: |
2021
|
| Sorozat: | ACTA PHARMACEUTICA HUNGARICA
91 No. 2 |
| Tárgyszavak: | |
| doi: | 10.33892/aph.2021.91.75-82 |
| mtmt: | 32530842 |
| Online Access: | http://publicatio.bibl.u-szeged.hu/24595 |
| LEADER | 02179nab a2200241 i 4500 | ||
|---|---|---|---|
| 001 | publ24595 | ||
| 005 | 20220628084516.0 | ||
| 008 | 220628s2021 hu o 0|| Angol d | ||
| 022 | |a 0001-6659 | ||
| 024 | 7 | |a 10.33892/aph.2021.91.75-82 |2 doi | |
| 024 | 7 | |a 32530842 |2 mtmt | |
| 040 | |a SZTE Publicatio Repozitórium |b hun | ||
| 041 | |a Angol | ||
| 100 | 1 | |a Benke Edit | |
| 245 | 1 | 0 | |a Development of meloxicam potassium-containing co-spray-dried inhalation powder with sodium stearate |h [elektronikus dokumentum] / |c Benke Edit |
| 260 | |c 2021 | ||
| 300 | |a 75-82 | ||
| 490 | 0 | |a ACTA PHARMACEUTICA HUNGARICA |v 91 No. 2 | |
| 520 | 3 | |a Pulmonary drug delivery (PDD) has potential for both local and systemic therapy. Our research group is focus- ing on the development of dry powder inhalation (DPI) systems for PDD due to their beneficial properties. Although there is not yet a marketed inhalation product for non-steroidal anti-inflammatory drugs (NSAIDs), their therapeutic use in sev- eral lung diseases is well established and successful DPI developments have been performed with them. Sodium stearate (NaSt) is a promising excipient for DPI development, but its role in NSAIDs has not yet been investigated. Thus, the aim was to study DPI samples produced by co-spray-drying, applying meloxicam potassium (MXP) as an NSAID drug, and different concentrations (0-2 w/w%) of NaSt. Physicochemical investigations, in vitro lung deposition, and in vitro drug release measurements were performed. It can be stated that co-spray-drying of MXP with NaSt resulted in remarkable morphological differences by increasing the concentration of NaSt, which had a positive effect on cohesive work. Further- more, applying of NaSt accelerates the dissolution in simulated lung fluid (SLF). NaSt as excipient has a future for the formulation of the DPI systems because there are in the development focus the attaintment of the higher FPF values and improvement of dissolution in SLF. | |
| 650 | 4 | |a Általános orvostudomány | |
| 700 | 0 | 1 | |a Révész Piroska |e aut |
| 700 | 0 | 1 | |a Ambrus Rita |e aut |
| 856 | 4 | 0 | |u http://publicatio.bibl.u-szeged.hu/24595/1/46-ArticleText-1233-1-10-20211121.pdf |z Dokumentum-elérés |